ReviewCurrent opinion in oncology2014
Oropharyngeal squamous cell carcinoma treatment: current standards and future directions.
Review in Current opinion in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- How Would You Treat? A Case-Vignette Study of Provider Treatment Preferences in Human Papillomavirus-Mediated Oropharyngeal Cancer.Head & neck · 2026Article
- Deciphering the Genomic Landscape of Oropharyngeal Squamous Cell Carcinoma: Distinct Mutation Patterns in Disease.Life (Basel, Switzerland) · 2026Article
- The efficacy and safety of the addition of programmed cell death protein 1 inhibitor to preoperative chemotherapy in locoregionally advanced oropharyngeal carcinoma.Translational cancer research · 2025Article
- MRI for Differentiation between HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Systematic Review.Cancers · 2024Review
- Gene-Expression Patterns of Tumor and Peritumor Tissues of Smoking and Non-Smoking HPV-Negative Patients with Head and Neck Squamous Cell Carcinoma.Biomedicines · 2024Article
- A novel systematic approach for cancer treatment prognosis and its applications in oropharyngeal cancer with microRNA biomarkers.Bioinformatics (Oxford, England) · 2021Article
- Human papillomavirus infection predicts a better survival rate in patients with oropharyngeal cancer.Archives of medical science : AMS · 2021Article
- Characterization of high risk human papilloma virus genotypes associated with oropharyngeal cancers in a Nigerian population.The Pan African medical journal · 2021Article
- Radiotherapy volume delineation using dynamic [International journal of computer assisted radiology and surgery · 2016Article
- Oral and Oropharyngeal Reconstruction with a Free Flap.Archives of craniofacial surgery · 2016Review
- Article
- Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewTo discuss the changing landscape and significant developments in the diagnosis and management of oropharyngeal squamous cell carcinoma. RECENT
findingsHigh-risk human papilloma viruses (HPVs) have been recognized as important causative factors for oropharyngeal cancer. The diagnosis is established with type-specific and broad-spectrum in-situ hybridization probes and/or p16 immunohistochemistry assays on fresh frozen paraffin-embedded tissue blocks. HPV-associated tumors have superior response and outcomes compared with HPV-unrelated tumors. Retrospective studies have been able to stratify oropharyngeal squamous cell carcinoma based on HPV status, tumor stage, nodal stage, and smoking history into risk groups with differing risks of death or distant disease. Selected patients, nonsmokers with less advanced nodal stage, may be overtreated with current treatment paradigms, and deintensification of curative therapy is a current research focus for these patients. Smokers, patients with advanced nodal or tumor stage, and those with HPV-unrelated cancers have a less favorable prognosis and the search for novel targets is particularly important for these patients. SUMMARY: The present review will highlight the current standards and the future direction of novel therapies in both HPV-associated and HPV-unrelated cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.